232 related articles for article (PubMed ID: 25256077)
1. High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients.
Miyoshi Y; Uemura H; Umemoto S; Sakamaki K; Morita S; Suzuki K; Shibata Y; Masumori N; Ichikawa T; Mizokami A; Sugimura Y; Nonomura N; Sakai H; Honma S; Harada M; Kubota Y
BMC Cancer; 2014 Sep; 14():717. PubMed ID: 25256077
[TBL] [Abstract][Full Text] [Related]
2. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
[TBL] [Abstract][Full Text] [Related]
3. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
[TBL] [Abstract][Full Text] [Related]
4. Low serum dehydroepiandrosterone examined by liquid chromatography-tandem mass spectrometry correlates with poor prognosis in hormone-naïve prostate cancer.
Miyoshi Y; Uemura H; Umemoto S; Sakamaki K; Taguri M; Suzuki K; Shibata Y; Masumori N; Ichikawa T; Mizokami A; Sugimura Y; Nonomura N; Sakai H; Honma S; Harada M; Kubota Y
Prostate; 2016 Mar; 76(4):376-82. PubMed ID: 26616365
[TBL] [Abstract][Full Text] [Related]
5. The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression.
Belledant A; Hovington H; Garcia L; Caron P; Brisson H; Villeneuve L; Simonyan D; Têtu B; Fradet Y; Lacombe L; Guillemette C; Lévesque E
Eur Urol; 2016 Apr; 69(4):601-609. PubMed ID: 26215610
[TBL] [Abstract][Full Text] [Related]
6. Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population.
Gustafsson O; Norming U; Gustafsson S; Eneroth P; Aström G; Nyman CR
Br J Urol; 1996 Mar; 77(3):433-40. PubMed ID: 8814852
[TBL] [Abstract][Full Text] [Related]
7. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
Freedland SJ; Aronson WJ; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Terris MK;
Urology; 2003 Apr; 61(4):742-7. PubMed ID: 12670558
[TBL] [Abstract][Full Text] [Related]
8. Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy.
Vance SM; Stenmark MH; Blas K; Halverson S; Hamstra DA; Feng FY
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):940-6. PubMed ID: 22056069
[TBL] [Abstract][Full Text] [Related]
9. Prediction of tumour volume and pathological stage in radical prostatectomy specimens is not improved by taking more prostate needle-biopsy cores.
Grossklaus DJ; Coffey CS; Shappell SB; Jack GS; Cookson MS
BJU Int; 2001 Nov; 88(7):722-6. PubMed ID: 11890243
[TBL] [Abstract][Full Text] [Related]
10. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
11. Associations of pretreatment serum total testosterone measurements with pathology-detected Gleason score cancer.
Porcaro AB; Petrozziello A; Ghimenton C; Migliorini F; Sava T; Caruso B; Romano M; Cavalleri S; Artibani W
Urol Int; 2014; 93(3):269-78. PubMed ID: 24334919
[TBL] [Abstract][Full Text] [Related]
12. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
Makarov DV; Sanderson H; Partin AW; Epstein JI
J Urol; 2002 Jun; 167(6):2440-2. PubMed ID: 11992053
[TBL] [Abstract][Full Text] [Related]
13. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
García-Cruz E; Piqueras M; Huguet J; Peri L; Izquierdo L; Musquera M; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
BJU Int; 2012 Dec; 110(11 Pt B):E541-6. PubMed ID: 22584031
[TBL] [Abstract][Full Text] [Related]
14. Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml.
Shiota M; Takeuchi A; Sugimoto M; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
Anticancer Res; 2015 Nov; 35(11):6137-45. PubMed ID: 26504040
[TBL] [Abstract][Full Text] [Related]
15. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men.
Kjaer TN; Ornstrup MJ; Poulsen MM; Jørgensen JO; Hougaard DM; Cohen AS; Neghabat S; Richelsen B; Pedersen SB
Prostate; 2015 Sep; 75(12):1255-63. PubMed ID: 25939591
[TBL] [Abstract][Full Text] [Related]
17. Predicting the risk of harboring high-grade disease for patients diagnosed with prostate cancer scored as Gleason ≤ 6 on biopsy cores.
Seisen T; Roudot-Thoraval F; Bosset PO; Beaugerie A; Allory Y; Vordos D; Abbou CC; De La Taille A; Salomon L
World J Urol; 2015 Jun; 33(6):787-92. PubMed ID: 24985552
[TBL] [Abstract][Full Text] [Related]
18. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Suzuki K; Takahashi K
J Urol; 2006 Oct; 176(4 Pt 1):1387-91. PubMed ID: 16952639
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy.
Freedland SJ; Csathy GS; Dorey F; Aronson WJ
Urology; 2002 Jul; 60(1):84-8. PubMed ID: 12100929
[TBL] [Abstract][Full Text] [Related]
20. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms.
Gancarczyk KJ; Wu H; McLeod DG; Kane C; Kusuda L; Lance R; Herring J; Foley J; Baldwin D; Bishoff JT; Soderdahl D; Moul JW
Urology; 2003 Mar; 61(3):589-95. PubMed ID: 12639653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]